Cargando…

Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up

BACKGROUND: Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited. METHODS: This is a retrospective analysis of new thrombotic events among primary APS (pAPS) patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Niznik, Stanley, Rapoport, Micha J., Avnery, Orly, Lubetsky, Aharon, Haj Yahia, Soad, Ellis, Martin H., Agmon-Levin, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063725/
https://www.ncbi.nlm.nih.gov/pubmed/35514968
http://dx.doi.org/10.3389/fimmu.2022.843718
_version_ 1784699221109112832
author Niznik, Stanley
Rapoport, Micha J.
Avnery, Orly
Lubetsky, Aharon
Haj Yahia, Soad
Ellis, Martin H.
Agmon-Levin, Nancy
author_facet Niznik, Stanley
Rapoport, Micha J.
Avnery, Orly
Lubetsky, Aharon
Haj Yahia, Soad
Ellis, Martin H.
Agmon-Levin, Nancy
author_sort Niznik, Stanley
collection PubMed
description BACKGROUND: Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited. METHODS: This is a retrospective analysis of new thrombotic events among primary APS (pAPS) patients followed for up to 15 years in three medical centers in Israel. RESULTS: Among 312 primary-APS patients, 143 (46%) had new thrombotic event classified to three patterns: (1) Arterial—associated with heart valve disease (OR 7.24, 95% C.I. 2.26–24.6), hypertension (OR 3, 95% C.I. 1.44–6.25), elevated anti-B2-GPI IgM (OR 1.04, 95% C.I. 0.996–1.08), arterial thrombosis at presentation (OR 1.74 95% C.I. 0.992–3.26), and older age (41 vs. 34 years, p < 0.001). (2) Venous—linked with venous thrombosis at presentation (OR 12.9, 95% C.I. 5.27–31.6, p < 0.001), heart valve disease (OR 9.81 95% C.I. 1.82–52.9, p = 0.018), aGAPSS (OR 1.15 95% C.I. 1.02–1.29), and younger age (31 vs. 36.5 years, p = 0.001); and (3) Combined pattern—associated with heart valve disease (OR 40.5 95% C.I. 7.7–212) and pulmonary embolism (OR 7.47 95% C.I. 1.96–28.5). A 4th variant “the Breakthrough pattern” defined by re-thrombosis despite prophylactic therapy was observed in 100/143 (70%) patients and linked with heart valve disease (OR 8. 95% C.I. 2.43–26.3), venous thrombosis at presentation (OR 2.61 95% C.I. 1.47–4.66), leg ulcers (OR 12.2, 95% C.I. 1.4–107), hypertension (OR 1.99, 95% C.I. 0.92–4.34), and higher aGAPSS (OR 1.08, 95% C.I. 0.99–1.18). CONCLUSION: In this real-life observation, re-thrombosis was common among pAPS patients including in those recommended to receive prophylactic therapy. Different patterns of recurrence were identified and linked with presenting symptoms, specific serological markers, APS manifestations, and comorbidities. Studies that will address interventions to prevent recurrences of APS-related events are needed.
format Online
Article
Text
id pubmed-9063725
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90637252022-05-04 Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up Niznik, Stanley Rapoport, Micha J. Avnery, Orly Lubetsky, Aharon Haj Yahia, Soad Ellis, Martin H. Agmon-Levin, Nancy Front Immunol Immunology BACKGROUND: Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited. METHODS: This is a retrospective analysis of new thrombotic events among primary APS (pAPS) patients followed for up to 15 years in three medical centers in Israel. RESULTS: Among 312 primary-APS patients, 143 (46%) had new thrombotic event classified to three patterns: (1) Arterial—associated with heart valve disease (OR 7.24, 95% C.I. 2.26–24.6), hypertension (OR 3, 95% C.I. 1.44–6.25), elevated anti-B2-GPI IgM (OR 1.04, 95% C.I. 0.996–1.08), arterial thrombosis at presentation (OR 1.74 95% C.I. 0.992–3.26), and older age (41 vs. 34 years, p < 0.001). (2) Venous—linked with venous thrombosis at presentation (OR 12.9, 95% C.I. 5.27–31.6, p < 0.001), heart valve disease (OR 9.81 95% C.I. 1.82–52.9, p = 0.018), aGAPSS (OR 1.15 95% C.I. 1.02–1.29), and younger age (31 vs. 36.5 years, p = 0.001); and (3) Combined pattern—associated with heart valve disease (OR 40.5 95% C.I. 7.7–212) and pulmonary embolism (OR 7.47 95% C.I. 1.96–28.5). A 4th variant “the Breakthrough pattern” defined by re-thrombosis despite prophylactic therapy was observed in 100/143 (70%) patients and linked with heart valve disease (OR 8. 95% C.I. 2.43–26.3), venous thrombosis at presentation (OR 2.61 95% C.I. 1.47–4.66), leg ulcers (OR 12.2, 95% C.I. 1.4–107), hypertension (OR 1.99, 95% C.I. 0.92–4.34), and higher aGAPSS (OR 1.08, 95% C.I. 0.99–1.18). CONCLUSION: In this real-life observation, re-thrombosis was common among pAPS patients including in those recommended to receive prophylactic therapy. Different patterns of recurrence were identified and linked with presenting symptoms, specific serological markers, APS manifestations, and comorbidities. Studies that will address interventions to prevent recurrences of APS-related events are needed. Frontiers Media S.A. 2022-04-19 /pmc/articles/PMC9063725/ /pubmed/35514968 http://dx.doi.org/10.3389/fimmu.2022.843718 Text en Copyright © 2022 Niznik, Rapoport, Avnery, Lubetsky, Haj Yahia, Ellis and Agmon-Levin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Niznik, Stanley
Rapoport, Micha J.
Avnery, Orly
Lubetsky, Aharon
Haj Yahia, Soad
Ellis, Martin H.
Agmon-Levin, Nancy
Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up
title Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up
title_full Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up
title_fullStr Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up
title_full_unstemmed Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up
title_short Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome—Multicenter, Real-Life Long-Term Follow-Up
title_sort patterns of recurrent thrombosis in primary antiphospholipid syndrome—multicenter, real-life long-term follow-up
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063725/
https://www.ncbi.nlm.nih.gov/pubmed/35514968
http://dx.doi.org/10.3389/fimmu.2022.843718
work_keys_str_mv AT niznikstanley patternsofrecurrentthrombosisinprimaryantiphospholipidsyndromemulticenterreallifelongtermfollowup
AT rapoportmichaj patternsofrecurrentthrombosisinprimaryantiphospholipidsyndromemulticenterreallifelongtermfollowup
AT avneryorly patternsofrecurrentthrombosisinprimaryantiphospholipidsyndromemulticenterreallifelongtermfollowup
AT lubetskyaharon patternsofrecurrentthrombosisinprimaryantiphospholipidsyndromemulticenterreallifelongtermfollowup
AT hajyahiasoad patternsofrecurrentthrombosisinprimaryantiphospholipidsyndromemulticenterreallifelongtermfollowup
AT ellismartinh patternsofrecurrentthrombosisinprimaryantiphospholipidsyndromemulticenterreallifelongtermfollowup
AT agmonlevinnancy patternsofrecurrentthrombosisinprimaryantiphospholipidsyndromemulticenterreallifelongtermfollowup